s-1-(combination) and Gastroesophageal-Reflux

s-1-(combination) has been researched along with Gastroesophageal-Reflux* in 1 studies

Trials

1 trial(s) available for s-1-(combination) and Gastroesophageal-Reflux

ArticleYear
Proton-pump inhibitor as palliative care for chemotherapy-induced gastroesophageal reflux disease in pancreatic cancer patients.
    Journal of palliative medicine, 2010, Volume: 13, Issue:7

    Relief of adverse events induced by chemotherapy is an important issue for patients, especially those with a poor prognosis, such as with pancreatic cancer. There are no reports of the relationship between gastroesophageal reflux disease (GERD) and chemotherapy, so we investigated the incidence of chemotherapy-induced GERD in patients undergoing treatment with gemcitabine or S-1 for pancreatic cancer and the effect of sodium rabeprazole (RPZ), a proton-pump inhibitor. GERD was diagnosed in 40% of the patients according to the Frequency Scale for Symptoms of GERD score, and RBZ therapy significantly improved their symptoms.

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gastroesophageal Reflux; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Tegafur

2010